Published in Glycobiology on September 21, 2005
Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res (2007) 2.30
Glycomics and disease markers. Curr Opin Chem Biol (2009) 2.04
The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics (2009) 1.52
Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. Mol Immunol (2007) 1.45
Carbohydrate recognition by boronolectins, small molecules, and lectins. Med Res Rev (2010) 1.44
Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res (2009) 1.30
Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem (2009) 1.17
Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal Chem (2010) 1.16
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. Anal Chem (2011) 1.15
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res (2009) 1.13
Glycomic analysis of sialic acid linkages in glycans derived from blood serum glycoproteins. J Proteome Res (2010) 1.13
N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation. Mol Cell Proteomics (2012) 1.11
Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci U S A (2012) 1.09
A strategy for precise and large scale identification of core fucosylated glycoproteins. Mol Cell Proteomics (2009) 1.03
Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics (2013) 1.03
Aberrant PSA glycosylation--a sweet predictor of prostate cancer. Nat Rev Urol (2013) 1.03
Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. Theranostics (2015) 0.96
Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med (2009) 0.95
Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells. Bioorg Med Chem Lett (2011) 0.90
N-glycan profiling by microchip electrophoresis to differentiate disease states related to esophageal adenocarcinoma. Anal Chem (2012) 0.89
Serum glycan signatures of gastric cancer. Cancer Prev Res (Phila) (2013) 0.88
Toward a prostate specific antigen-based prostate cancer diagnostic assay: preparation of keyhole limpet hemocyanin-conjugated normal and transformed prostate specific antigen fragments. J Am Chem Soc (2008) 0.87
A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma. Electrophoresis (2010) 0.86
Glycoproteomics: identifying the glycosylation of prostate specific antigen at normal and high isoelectric points by LC-MS/MS. J Proteome Res (2014) 0.85
Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling. J Proteome Res (2011) 0.85
Integration of the transcriptome and glycome for identification of glycan cell signatures. PLoS Comput Biol (2013) 0.85
Glycosylation potential of human prostate cancer cell lines. Glycoconj J (2012) 0.85
Profiles of carbohydrate ligands associated with adsorbed proteins on self-assembled monolayers of defined chemistries. J Biomed Mater Res A (2010) 0.84
Evaluation of riproximin binding properties reveals a novel mechanism for cellular targeting. J Biol Chem (2012) 0.83
Development of recombinant Aleuria aurantia lectins with altered binding specificities to fucosylated glycans. Biochem Biophys Res Commun (2011) 0.83
Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes. Theranostics (2016) 0.82
Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry. Clin Biochem (2011) 0.82
Exploring the glycosylation of serum CA125. Int J Mol Sci (2013) 0.82
Prediction of glycan motifs using quantitative analysis of multi-lectin binding: Motifs on MUC1 produced by cultured pancreatic cancer cells. Proteomics Clin Appl (2013) 0.81
DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER. Curr Proteomics (2010) 0.79
Characterization of the Glycosylation Site of Human PSA Prompted by Missense Mutation using LC-MS/MS. J Proteome Res (2015) 0.79
Expression of LacdiNAc groups on N-glycans among human tumors is complex. Biomed Res Int (2014) 0.77
Structural Characterization of Serum N-Glycans by Methylamidation, Fluorescent Labeling, and Analysis by Microchip Electrophoresis. Anal Chem (2016) 0.77
Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples. J Proteomics (2011) 0.76
Can glycoprofiling be helpful in detecting prostate cancer? (2014) 0.76
Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia. Dis Markers (2016) 0.75
Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection. Int J Mol Sci (2017) 0.75
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol (2007) 4.96
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol (2002) 3.53
Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology (2003) 3.19
Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature (2007) 3.01
Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics (2009) 2.93
Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology (2007) 2.71
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A (2003) 2.64
Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol (2008) 2.63
Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med (2007) 2.57
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A (2010) 2.51
Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet (2004) 2.45
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology (2007) 2.45
Glycoprotein structural genomics: solving the glycosylation problem. Structure (2007) 2.40
Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res (2009) 2.39
A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol (2010) 2.30
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog (2008) 2.09
Conformational studies of oligosaccharides and glycopeptides: complementarity of NMR, X-ray crystallography, and molecular modelling. Chem Rev (2002) 2.02
The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One (2011) 1.95
Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics (2008) 1.94
HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem (2007) 1.92
Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology (2003) 1.91
Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc Natl Acad Sci U S A (2002) 1.88
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci U S A (2007) 1.84
Emerging principles for the therapeutic exploitation of glycosylation. Science (2014) 1.83
Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol (2002) 1.80
High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics (2011) 1.70
Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. J Biol Chem (2003) 1.68
Glycans as cancer biomarkers. Biochim Biophys Acta (2011) 1.66
Storage solutions: treating lysosomal disorders of the brain. Nat Rev Neurosci (2005) 1.65
GlycoBase and autoGU: tools for HPLC-based glycan analysis. Bioinformatics (2008) 1.64
A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology (2008) 1.55
Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet (2013) 1.52
Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem (2007) 1.52
Genes contributing to prion pathogenesis. J Gen Virol (2008) 1.51
Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis (2004) 1.50
Structural and quantitative analysis of N-linked glycans by matrix-assisted laser desorption ionization and negative ion nanospray mass spectrometry. Anal Biochem (2008) 1.49
Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology (2007) 1.49
Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem (2005) 1.47
The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci U S A (2009) 1.44
Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods Mol Biol (2006) 1.43
Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1α as a master regulator of plasma protein fucosylation. PLoS Genet (2010) 1.43
Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling. Anal Biochem (2004) 1.42
Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew Chem Int Ed Engl (2004) 1.41
Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. J Mol Biol (2007) 1.41
Molecular mechanism of lipopeptide presentation by CD1a. Immunity (2005) 1.41
Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology (2010) 1.39
Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood (2003) 1.39
Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology (2010) 1.37
The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem (2006) 1.36
Novel glycan biomarkers for the detection of lung cancer. J Proteome Res (2011) 1.33
Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol (2007) 1.33
Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology (2003) 1.32
Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology (2005) 1.31
Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers (2008) 1.27
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum (2010) 1.25
Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem (2010) 1.25
An analytical and structural database provides a strategy for sequencing O-glycans from microgram quantities of glycoproteins. Anal Biochem (2002) 1.25
Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. J Biol Chem (2004) 1.22
Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol Lett (2006) 1.21
Towards complete analysis of the platelet proteome. Proteomics (2002) 1.21